Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 42.03 -1.22% -0.52
IONS closed down 1.22 percent on Monday, March 18, 2024, on 81 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Inside Day Range Contraction -1.22%
Oversold Stochastic Weakness -1.22%
Stochastic Buy Signal Bullish -0.36%
Down 3 Days in a Row Weakness -0.36%
Down 4 Days in a Row Weakness -0.36%
Down 5 Days in a Row Weakness -0.36%
Lower Bollinger Band Touch Weakness -0.36%
Oversold Stochastic Weakness -0.36%

   Recent Intraday Alerts

Alert Time
Down 1% about 12 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Rose Above Previous Day's High about 18 hours ago
Up 1% 4 days ago
Possible Inside Day 4 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ionis Pharmaceuticals, Inc. Description

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Organ Systems Diabetes Alcohol Rare Diseases Drug Discovery Genetics Disorders Prostate Cancer Neurological Disorders Lipid Hepatitis B Obesity Dystrophy Multiple Sclerosis Steatohepatitis Orphan Drug Cholesterol Hepatitis C Amyloid Amyloidosis Hepatitis C Virus Huntington's Disease Hepatitis B Virus Angioedema Hereditary Angioedema Cardiomyopathy Dyslipidemia Hypercholesterolemia Myopathy Spinal Muscular Atrophy Treatment Of Diabetes Myotonic Dystrophy Severe And Rare Diseases Therapeutic Gene Modulation Acromegaly Antisense RNA Hepatitis C Virus Infection Alport Syndrome Apatorsen Cushing's Syndrome Familial Amyloid Polyneuropathy Homozygous Familial Hypercholesterolemia Ionis Lipodystrophy Mixed Dyslipidemia Ocular Disease Onemia Polyneuropathy TTR Amyloidosis

Is IONS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 54.4446
52 Week Low 32.87
Average Volume 1,196,410
200-Day Moving Average 45.21
50-Day Moving Average 48.10
20-Day Moving Average 44.32
10-Day Moving Average 43.35
Average True Range 1.31
RSI (14) 31.51
ADX 19.05
+DI 16.65
-DI 26.49
Chandelier Exit (Long, 3 ATRs) 45.93
Chandelier Exit (Short, 3 ATRs) 45.60
Upper Bollinger Bands 47.10
Lower Bollinger Band 41.53
Percent B (%b) 0.09
BandWidth 12.58
MACD Line -1.56
MACD Signal Line -1.47
MACD Histogram -0.096
Fundamentals Value
Market Cap 6.03 Billion
Num Shares 143 Million
EPS -2.87
Price-to-Earnings (P/E) Ratio -14.64
Price-to-Sales 11.75
Price-to-Book 23.37
PEG Ratio 25.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.24
Resistance 3 (R3) 43.35 43.06 43.04
Resistance 2 (R2) 43.06 42.76 43.01 42.97
Resistance 1 (R1) 42.55 42.57 42.40 42.43 42.90
Pivot Point 42.26 42.26 42.19 42.20 42.26
Support 1 (S1) 41.74 41.95 41.60 41.63 41.16
Support 2 (S2) 41.45 41.76 41.40 41.09
Support 3 (S3) 40.94 41.45 41.02
Support 4 (S4) 40.82